Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
43
TNDM Quote, Financials, Valuation and Earnings
Last price:
$15.36
Seasonality move
:
2.02%
Day range:
$15.19 - $15.93
52-week range:
$14.87 - $48.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.05x
P/B ratio:
6.76x
Volume:
1.8M
Avg. volume:
1.6M
1-year change:
-66.48%
Market cap:
$1B
Revenue:
$940.2M
EPS (TTM):
-$2.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
$238.4M | -$0.40 | 7.28% | -14.02% | $31.70 |
|
ABT
Abbott Laboratories
|
$11.1B | $1.26 | 6.75% | 41.8% | $142.55 |
|
ATEC
Alphatec Holdings
|
$178.9M | -$0.05 | 22.86% | -82.07% | $18.32 |
|
BBNX
Beta Bionics
|
$19.7M | -$0.47 | -- | -- | $23.56 |
|
PODD
Insulet
|
$612.3M | $0.92 | 25.31% | -64.13% | $336.85 |
|
UFPT
UFP Technologies
|
$151.6M | $2.25 | 37.56% | 28.57% | $311.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
$15.75 | $31.70 | $1B | -- | $0.00 | 0% | 1.05x |
|
ABT
Abbott Laboratories
|
$131.74 | $142.55 | $229.2B | 17.09x | $0.59 | 1.76% | 5.44x |
|
ATEC
Alphatec Holdings
|
$10.63 | $18.32 | $1.6B | -- | $0.00 | 0% | 2.39x |
|
BBNX
Beta Bionics
|
$12.66 | $23.56 | $548.9M | -- | $0.00 | 0% | -- |
|
PODD
Insulet
|
$288.27 | $336.85 | $20.3B | 51.85x | $0.00 | 0% | 9.70x |
|
UFPT
UFP Technologies
|
$228.68 | $311.00 | $1.8B | 27.99x | $0.00 | 0% | 3.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
69.23% | 2.042 | 27.4% | 1.72x |
|
ABT
Abbott Laboratories
|
21.34% | 0.677 | 6.18% | 1.27x |
|
ATEC
Alphatec Holdings
|
118.58% | 1.593 | 36.81% | 1.54x |
|
BBNX
Beta Bionics
|
-- | 0.000 | -- | -- |
|
PODD
Insulet
|
56.03% | 1.967 | 9.18% | 3.24x |
|
UFPT
UFP Technologies
|
33.63% | 3.051 | 11.76% | 1.39x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNDM
Tandem Diabetes Care
|
$118.4M | -$120.9M | -31.97% | -81.14% | -51.5% | -$64.7M |
|
ABT
Abbott Laboratories
|
$5.9B | $1.7B | 23.5% | 31.31% | 18.43% | $933M |
|
ATEC
Alphatec Holdings
|
$116M | -$31.7M | -31.36% | -691.37% | -26.09% | -$16.7M |
|
BBNX
Beta Bionics
|
-- | -- | -- | -- | -- | -- |
|
PODD
Insulet
|
$409M | $88.8M | 15.79% | 36.9% | 10.07% | $48.1M |
|
UFPT
UFP Technologies
|
$42.2M | $23.4M | 13.85% | 19.38% | 15.59% | $11M |
Tandem Diabetes Care vs. Competitors
-
Which has Higher Returns TNDM or ABT?
Abbott Laboratories has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 12.79%. Tandem Diabetes Care's return on equity of -81.14% beat Abbott Laboratories's return on equity of 31.31%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M ABTAbbott Laboratories56.86% $0.76 $62.3B -
What do Analysts Say About TNDM or ABT?
Tandem Diabetes Care has a consensus price target of $31.70, signalling upside risk potential of 101.27%. On the other hand Abbott Laboratories has an analysts' consensus of $142.55 which suggests that it could grow by 8.2%. Given that Tandem Diabetes Care has higher upside potential than Abbott Laboratories, analysts believe Tandem Diabetes Care is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care6 10 1 ABTAbbott Laboratories12 9 0 -
Is TNDM or ABT More Risky?
Tandem Diabetes Care has a beta of 1.478, which suggesting that the stock is 47.763% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.93%.
-
Which is a Better Dividend Stock TNDM or ABT?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.76% to investors and pays a quarterly dividend of $0.59 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TNDM or ABT?
Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Abbott Laboratories quarterly revenues of $10.4B. Tandem Diabetes Care's net income of -$130.6M is lower than Abbott Laboratories's net income of $1.3B. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 17.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.05x versus 5.44x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.05x -- $234.4M -$130.6M ABTAbbott Laboratories5.44x 17.09x $10.4B $1.3B
-
Which has Higher Returns TNDM or ATEC?
Alphatec Holdings has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of -30.68%. Tandem Diabetes Care's return on equity of -81.14% beat Alphatec Holdings's return on equity of -691.37%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M ATECAlphatec Holdings68.56% -$0.35 $462.5M -
What do Analysts Say About TNDM or ATEC?
Tandem Diabetes Care has a consensus price target of $31.70, signalling upside risk potential of 101.27%. On the other hand Alphatec Holdings has an analysts' consensus of $18.32 which suggests that it could grow by 72.33%. Given that Tandem Diabetes Care has higher upside potential than Alphatec Holdings, analysts believe Tandem Diabetes Care is more attractive than Alphatec Holdings.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care6 10 1 ATECAlphatec Holdings5 1 0 -
Is TNDM or ATEC More Risky?
Tandem Diabetes Care has a beta of 1.478, which suggesting that the stock is 47.763% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.249%.
-
Which is a Better Dividend Stock TNDM or ATEC?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or ATEC?
Tandem Diabetes Care quarterly revenues are $234.4M, which are larger than Alphatec Holdings quarterly revenues of $169.2M. Tandem Diabetes Care's net income of -$130.6M is lower than Alphatec Holdings's net income of -$51.9M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.05x versus 2.39x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.05x -- $234.4M -$130.6M ATECAlphatec Holdings2.39x -- $169.2M -$51.9M
-
Which has Higher Returns TNDM or BBNX?
Beta Bionics has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of --. Tandem Diabetes Care's return on equity of -81.14% beat Beta Bionics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M BBNXBeta Bionics-- -- -- -
What do Analysts Say About TNDM or BBNX?
Tandem Diabetes Care has a consensus price target of $31.70, signalling upside risk potential of 101.27%. On the other hand Beta Bionics has an analysts' consensus of $23.56 which suggests that it could grow by 86.06%. Given that Tandem Diabetes Care has higher upside potential than Beta Bionics, analysts believe Tandem Diabetes Care is more attractive than Beta Bionics.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care6 10 1 BBNXBeta Bionics6 2 0 -
Is TNDM or BBNX More Risky?
Tandem Diabetes Care has a beta of 1.478, which suggesting that the stock is 47.763% more volatile than S&P 500. In comparison Beta Bionics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TNDM or BBNX?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beta Bionics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Beta Bionics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or BBNX?
Tandem Diabetes Care quarterly revenues are $234.4M, which are larger than Beta Bionics quarterly revenues of --. Tandem Diabetes Care's net income of -$130.6M is higher than Beta Bionics's net income of --. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Beta Bionics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.05x versus -- for Beta Bionics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.05x -- $234.4M -$130.6M BBNXBeta Bionics-- -- -- --
-
Which has Higher Returns TNDM or PODD?
Insulet has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 6.22%. Tandem Diabetes Care's return on equity of -81.14% beat Insulet's return on equity of 36.9%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M PODDInsulet71.88% $0.50 $3B -
What do Analysts Say About TNDM or PODD?
Tandem Diabetes Care has a consensus price target of $31.70, signalling upside risk potential of 101.27%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care6 10 1 PODDInsulet15 3 0 -
Is TNDM or PODD More Risky?
Tandem Diabetes Care has a beta of 1.478, which suggesting that the stock is 47.763% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.
-
Which is a Better Dividend Stock TNDM or PODD?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or PODD?
Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Insulet quarterly revenues of $569M. Tandem Diabetes Care's net income of -$130.6M is lower than Insulet's net income of $35.4M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.05x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.05x -- $234.4M -$130.6M PODDInsulet9.70x 51.85x $569M $35.4M
-
Which has Higher Returns TNDM or UFPT?
UFP Technologies has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 11.6%. Tandem Diabetes Care's return on equity of -81.14% beat UFP Technologies's return on equity of 19.38%.
Company Gross Margin Earnings Per Share Invested Capital TNDMTandem Diabetes Care50.51% -$1.97 $504.7M UFPTUFP Technologies28.45% $2.21 $543.4M -
What do Analysts Say About TNDM or UFPT?
Tandem Diabetes Care has a consensus price target of $31.70, signalling upside risk potential of 101.27%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 36%. Given that Tandem Diabetes Care has higher upside potential than UFP Technologies, analysts believe Tandem Diabetes Care is more attractive than UFP Technologies.
Company Buy Ratings Hold Ratings Sell Ratings TNDMTandem Diabetes Care6 10 1 UFPTUFP Technologies1 2 0 -
Is TNDM or UFPT More Risky?
Tandem Diabetes Care has a beta of 1.478, which suggesting that the stock is 47.763% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.208%.
-
Which is a Better Dividend Stock TNDM or UFPT?
Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNDM or UFPT?
Tandem Diabetes Care quarterly revenues are $234.4M, which are larger than UFP Technologies quarterly revenues of $148.1M. Tandem Diabetes Care's net income of -$130.6M is lower than UFP Technologies's net income of $17.2M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while UFP Technologies's PE ratio is 27.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.05x versus 3.25x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNDMTandem Diabetes Care1.05x -- $234.4M -$130.6M UFPTUFP Technologies3.25x 27.99x $148.1M $17.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 3.83% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 2.15% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.48% over the past day.
